 Home > Biochemistry News > Biotechnology News > Novartis DARPin protein therapy ensovibep failed to treat hospitalized COVID-19 patients!

Novartis DARPin protein therapy ensovibep failed to treat hospitalized COVID-19 patients!

 Last Update: 2022-01-01
 Source: Internet
 Author: User

Tags

ia 2 antibody

sub delivery

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compilenewborn

Another drug failed in the ACTIV-3 clinical trial

NIH conducted the ACTIV-3 trial to evaluate the effects of SARS-CoV-2 monoclonal antibodies and other therapies in hospitalized patients with COVID-19

Molecular Partners has advanced ensovibep to phase 3 studies, hoping that its difference from antibody therapy can help it achieve better results

However, regardless of the advantages of ensovibep, they have no effect on the results of the ACTIV-3 study

Patrick Amstutz, CEO of Molecular Partners, said in a statement that the failure of a series of drugs in ACTIV-3 "may be caused by the multi-system inflammatory component of the advanced COVID-19 disease

In October 2020, Novartis and Molecular Partners reached a cooperation to develop two DARPin protein therapies against COVID-19, including ensovibep

Reference source: Novartis-partnered DARPin flames out in COVID-19 study, sending Molecular Partners' stock into nosedive

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.